Statement from NIH and BARDA on the Novavax COVID-19 Vaccine

Laden...

2 jaren geleden

Html
Tekst

Having trouble viewing this email? View it as a Web page.

You are receiving this message because you are subscribed to News Releases for National Institutes of Health (NIH).

Statement from NIH and BARDA on the Novavax COVID-19 Vaccine 07/20/2022 11:00 AM EDT
The Centers for Disease Control and Prevention has recommended that Novavaxs COVID-19 vaccine be used as another primary series option for adults in the United States ages 18 years and older.

Update Your E-mail Address | Add Subscriptions | Unsubscribe All

If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. For all other inquiries about NIH programs and activities, please contact Ask NIH. Before writing, please view ourFrequently Asked Questions page, our Health Information page, or Search our website.

This service is provided to you by the National Institutes of Health.
NIHTurning Discovery Into Health

This email was sent to newsletter@newslettercollector.com using GovDelivery Communications Cloud on behalf of: National Institutes of Health (NIH) 9000 Rockville Pike Bethesda MD 20892 301-496-4000 / TTY 301-402-9612

Deel deze op

Laden...

Andere nieuwsbrieven van Niaid.nih.gov

Spotlight on Herbs and Other Botanicals Niaid.nih.gov
11 uren geleden
Find a plan for 2025! There is still time to enroll Niaid.nih.gov
15 uren geleden
HRSA Supports Rural Health Care Niaid.nih.gov
Afgelopen vrijdag om 18:07

Meer nieuwsbrieven van Niaid.nih.gov

Laden...

Statement from NIH and BARDA on the Novavax COVID-19 Vaccine

Deel deze op

Andere nieuwsbrieven van Niaid.nih.gov

Gerelateerde nieuwsbrieven